NCT05666128View on ClinicalTrials.gov

Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

June 17, 2022

Primary Completion Date

June 28, 2023

Study Completion Date

July 28, 2023

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

HD-6277

HD-6277 100mg

DRUG

HD-6277

HD-6277 50mg

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

Included Severance Hospital, 10 sites, Seoul

Sponsors

Lead Sponsor

Hyundai Pharm
All Listed Sponsors
lead

Hyundai Pharm

INDUSTRY